Premier Alternatives

Electra Therapeutics

Drug Discovery · South San Francisco, CA · Founded 2018 · Privately Held (backing)

Operator of a biotechnology company intended for the treatment of immunological diseases and cancer. Electra Therapeutics is based in South San Francisco, CA and was founded in 2018. It was valued at $479 million at its later-stage round in Oct 2025, the last priced event on record. It has raised $301 million across 2 recorded rounds; the latest was an $183 million Series C in Oct 2025.

PMV mark · valuation
$479.0M
Oct 2026
Priced at
its later-stage round
Oct 2025
Total raised
$301.0M
Last round
Later Stage VC (Series C)
Oct 2025

Electra Therapeutics key facts

as of Oct 2026
  • Operator of a biotechnology company intended for the treatment of immunological diseases and cancer.
  • Electra Therapeutics is valued at approximately $479.0M as of Oct 2026, set at its later-stage round, Oct 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $301.0M across 2 recorded rounds; the latest was Later Stage VC (Series C) ($183.0M) in Oct 2025.
  • Notable investors include RA Capital Management, OrbiMed, Blue Owl Capital, Cormorant Asset Management, EQT Life Sciences — 14 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$479.0M

Valued at $479.0M at its later-stage round, Oct 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Electra Therapeutics with a free account
  • ·The complete investor list: 14 names
  • ·Watch Electra Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Electra Therapeutics funding rounds

2 rounds
Oct 2025Later Stage VC (Series C)$183.0M▮
Feb 2022Early Stage VC (Series B)$84.0M▮
Full funding history →

Electra Therapeutics valuation

Electra Therapeutics was valued at $479 million at its later-stage round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Electra Therapeutics raised?

Electra Therapeutics has raised $301 million across 2 recorded rounds since 2022. The largest was an $84 million Series B in Feb 2022; the most recent was an $183 million Series C in Oct 2025.

Electra Therapeutics investors

14 investors are on record for Electra Therapeutics, including RA Capital Management, OrbiMed, Blue Owl Capital and Cormorant Asset Management. By type, the record holds 3 venture capital firms, 2 asset managers and 1 private equity firm. The Series C in Oct 2025 drew 11 investors.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Rivus Pharmaceuticals ($489 million), CORXEL Pharmaceuticals ($475 million) and Diagonal Therapeutics ($459 million).

About Electra Therapeutics

Operator of a biotechnology company intended for the treatment of immunological diseases and cancer. The company's lead product is a monoclonal antibody that targets a signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, enabling medical professionals to find an approved treatment for secondary hemophagocytic lymphohistiocytosis.

Industry
Drug Discovery
Sector
Healthcare
HQ
South San Francisco, CA, United States
Founded
2018
Employees
35
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.